Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

roche.com

Investor Update

Get the latest updates from Investor Update directly as they happen.

Follow now 187 followers

Latest posts

Last updated about 14 hours ago

Reminder: Invitation to Roche’s Half Year Results 2025 Presentation

2 days ago

  Roche will publish its Half Year Results of 2025 prior to the...

Invitation to Roche’s Half Year Results 2025 Presentation

23 days ago

  Roche will publish its Half Year Results of 2025 prior to the...

Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

26 days ago

Positive phase I/II data presented at the 2025 International Society on Thrombosis...

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

29 days ago

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival...

Reminder: Invitation to Roche’s Virtual Hematology Investor Event

about 1 month ago

  We are pleased to invite investors and analysts to participate in our...

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

about 1 month ago

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical...

Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

about 2 months ago

46% reduction in the risk of disease progression or death, and 27%...

New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

about 2 months ago

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than...

Invitation to Roche’s Virtual Hematology Investor Event

about 2 months ago

We are pleased to invite investors and analysts to participate in our...